The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Source: https://www.cnbc.com/2024/04/25/merck-m ... -2024.html
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
